Allergy Therapeutics plc

LSE AGY.L

Allergy Therapeutics plc Market Capitalization on January 14, 2025: USD 438.80 M

Allergy Therapeutics plc Market Capitalization is USD 438.80 M on January 14, 2025, a 28,835.74% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Allergy Therapeutics plc 52-week high Market Capitalization is USD 445.13 M on January 06, 2025, which is 1.44% above the current Market Capitalization.
  • Allergy Therapeutics plc 52-week low Market Capitalization is USD 1.51 M on January 16, 2024, which is -99.66% below the current Market Capitalization.
  • Allergy Therapeutics plc average Market Capitalization for the last 52 weeks is USD 258.36 M.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
LSE: AGY.L

Allergy Therapeutics plc

CEO Mr. Manuel Llobet
IPO Date Oct. 11, 2004
Location United Kingdom
Headquarters Dominion Way
Employees 612
Sector Health Care
Industries
Description

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

StockViz Staff

January 15, 2025

Any question? Send us an email